BioMarin Pharmaceutical (BMRN): Evaluating Valuation as PALYNZIQ Clinical Success Contrasts With 52-Week Share Price Low
BioMarin Pharmaceutical (BMRN) shares have landed at a 52-week low, just as the company announced new positive clinical results for its PALYNZIQ therapy in teens with phenylketonuria. This creates an interesting narrative for investors curious about the gap between BioMarin’s clinical momentum and market performance.
See our latest analysis for BioMarin Pharmaceutical.
Despite recently delivering encouraging clinical trial results for PALYNZIQ and a consistently growing revenue base, BioMarin Pharmaceutical’s share price recently touched a 52-week low at $55.57. While the 1-year total shareholder return sits at -18.5% and three-year returns are even softer, the combination of pipeline progress and improved earnings forecasts could…
